Pieter is a seasoned, scientifically driven Chief Executive with over two decades of experience in medical biotechnology. Known for his dynamic leadership and strategic foresight, he has expertise across the entire drug development spectrum, including discovery, preclinical research, clinical trials, and regulatory affairs in US and EU markets. Pieter excels in launching, revitalizing, and scaling biotech startups, driving innovation and sustainable growth.
He is adept at fostering relationships within the pharmaceutical industry and cultivating a broad network of investors across the US and EU. Pieter has held executive roles at ActoGeniX, Intrexon Corporation, and Precigen ActoBiotics, and served on the boards of Intrexon ActoBiotics NV and Precigen ActoBio, Inc. He has advanced multiple products from discovery to clinical trials in the autoimmune and inflammatory space, overseeing corporate strategy and operational excellence.
Pieter’s skills include entrepreneurial leadership, life science startup management, technology evaluation, research and clinical product development, global strategic alliances, business development, and investor relations. He holds a PhD in Biotechnology from the University of Ghent and has extensive experience as a principal investigator at the Flanders Institute for Biotechnology, combining scientific rigor with entrepreneurial flair.